Phase III Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection.

Trial Profile

Phase III Study of a Therapeutic Vaccine Candidate Containing Hepatitis B Virus (HBV) Core Antigen (HBcAg) and HBV Surface Antigen (HBsAg) for Treatment of Patients With Chronic HBV Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs ABX 203 (Primary) ; Peginterferon alfa-2b
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
    • 26 Apr 2013 Status changed from active, no longer recruiting to completed.
    • 26 Apr 2013 Primary endpoint 'Virological-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top